About Us
Mucommune is a privately-held R&D company. It was originally launched in 2016 based on the 'muco-trapping' monoclonal antibodies (mAb) platform developed at John Hopkins University and University of North Carolina at Chapel Hill. Mucommune's success in advancing technologies through preclinical studies over time led to its gradual transformation into a specialty R&D operation focused on bridging the gap between academic discoveries and clinical development.
Mucommune spun off Inhalon Biopharma in early 2019 to commercialize its pipeline of treatments for acute respiratory infections, while taking on a greater emphasis on addressing unmet needs in female reproductive health. It has since added tackling polymer immunogenicity to its R&D portfolio.
Mucommune is located in Discovery at Perimeter Park in the Research Triangle.
Meet The Team
Richard Cone, Ph.D. President
Academy Professor of Biophysics at Johns Hopkins University. Former Professor in Biophysics and Biology at Johns Hopkins University. Retired in 2017 to focus full time on advancing Mucommune. Over 25 years of experience advancing products for female reproductive health, bringing products into multiple Phase 3 clinical trials for contraception and HIV.
Keiichiro Kushiro, Ph.D.
VP of Research
Scott Hammers, B.S.,
Scientist
Thomas Moench, M.D.
VP Clinical Development,
CMO
Former infectious disease physician at Johns Hopkins. Over 30 years of R&D experience, including leading Phase 1 through Phase 3 clinical programs in antiviral mAb and female reproductive health
Morgan McSweeney, Ph.D., Assistant Director of Development
Janelle Tucker, B.S.,
Scientist
Sam Lai, Ph.D.
Founder & Interim CEO
Currently a Professor at UNC – Chapel Hill, and expert in mucosal health and infectious disease. IP developed at his lab in UNC formed the basis for Mucommune and Inhalon Biopharma; his prior inventions have led to multiple products that are either FDA-approved or in late stage clinical development.
Sean Hasso, Ph.D.,
Senior Scientist
